These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28182291)

  • 1. Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped.
    Gautier-Veyret E; Fonrose X; Stanke-Labesque F
    Clin Pharmacol Ther; 2017 Aug; 102(2):189. PubMed ID: 28182291
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole.
    Walsh TJ; Moriyama B; Penzak SR; Klein TE; Caudle KE
    Clin Pharmacol Ther; 2017 Aug; 102(2):190. PubMed ID: 28455946
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to "Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole".
    Walsh TJ; Moriyama B; Penzak SR; Klein TE; Caudle KE
    Clin Pharmacol Ther; 2018 Feb; 103(2):187. PubMed ID: 28786218
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of CYP3A4 Genotype on Voriconazole Exposure.
    Duflot T; Schrapp A; Bellien J; Lamoureux F
    Clin Pharmacol Ther; 2018 Feb; 103(2):185-186. PubMed ID: 28786228
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations.
    Gautier-Veyret E; Bailly S; Fonrose X; Tonini J; Chevalier S; Thiebaut-Bertrand A; Stanke-Labesque F
    Pharmacogenomics; 2017 Aug; 18(12):1119-1123. PubMed ID: 28745547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes.
    Shao B; Ma Y; Li Q; Wang Y; Zhu Z; Zhao H; Sun J; Dong L; Zhu Y; Zhao N; Qin Y
    Xenobiotica; 2017 Dec; 47(12):1121-1129. PubMed ID: 27937048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.
    Chuwongwattana S; Jantararoungtong T; Prommas S; Medhasi S; Puangpetch A; Sukasem C
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00665. PubMed ID: 33124772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genetic score combining CYP450 2C19 and 3A4 genotypes to predict voriconazole plasma exposure?
    Gautier-Veyret E; Fonrose X; Stanke-Labesque F
    Int J Antimicrob Agents; 2016 Aug; 48(2):221-2. PubMed ID: 27318623
    [No Abstract]   [Full Text] [Related]  

  • 9. Association of
    Zhao T; Shen H; Zhang HL; Feng J; Liu SM; Wang TT; Li HJ; Yu LH
    Pharmacogenomics; 2023 Feb; 24(3):141-151. PubMed ID: 36718992
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients.
    Fan X; Zhang H; Wen Z; Zheng X; Yang Y; Yang J
    Pharmacogenet Genomics; 2022 Jun; 32(4):152-158. PubMed ID: 35081606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies.
    Huang FR; Zhou C; Zhang XY; Shen Y; Zhang HW; Wang YQ; Sun LN
    Xenobiotica; 2021 Oct; 51(10):1199-1206. PubMed ID: 34402388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
    Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
    Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
    Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing.
    Patel JN; Robinson M; Morris SA; Jandrisevits E; Lopes KE; Hamilton A; Steuerwald N; Druhan LJ; Avalos B; Copelan E; Ghosh N; Grunwald MR
    Pharmacogenomics J; 2023 Nov; 23(6):201-209. PubMed ID: 37925536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of cytochrome P450 gene polymorphism in a lupus nephritis patient in whom tacrolimus blood concentration was markedly elevated after administration of azole antifungal agents.
    Fujita Y; Araki T; Okada Y; Aomori T; Shimizu R; Tomizawa T; Hiromura K; Nojima Y; Nakamura T; Yamamoto K
    J Clin Pharm Ther; 2013 Feb; 38(1):74-6. PubMed ID: 22971159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.
    Zhu L; Brüggemann RJ; Uy J; Colbers A; Hruska MW; Chung E; Sims K; Vakkalagadda B; Xu X; van Schaik RH; Burger DM; Bertz RJ
    J Clin Pharmacol; 2017 Feb; 57(2):235-246. PubMed ID: 27432796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
    Owusu Obeng A; Egelund EF; Alsultan A; Peloquin CA; Johnson JA
    Pharmacotherapy; 2014 Jul; 34(7):703-18. PubMed ID: 24510446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.
    Weiss J; Ten Hoevel MM; Burhenne J; Walter-Sack I; Hoffmann MM; Rengelshausen J; Haefeli WE; Mikus G
    J Clin Pharmacol; 2009 Feb; 49(2):196-204. PubMed ID: 19033450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
    Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.